Health Care & Life Sciences » Biotechnology | ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd.
Stock Exchange NYSE
EPS
$0.47
Market Cap
$784.05 K
Shares Outstanding
41.93 M
Public Float
41.75 M

Profile

Address
30721 Russell Ranch Road
Westlake Village California 91362
United States
Employees -
Website http://www.imuc.com
Updated 07/08/2019
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

Financials

View All
Created with Highcharts 5.0.14ImmunoCellular Therapeutics Ltd.Net Income. Fiscal year is January-December. All values USD Thousands.8 8008 8009 3779 37712 79012 79022 08522 08514 35314 3532013201420152016201705k10k15k20k25k

Gary S. Titus
Chairman & Secretary
Anthony J. Gringeri
President, Chief Executive Officer & Director